循环游离DNA:放化疗期间鉴别炎症与感染的潜在生物标志物
这项前瞻性生物标志物研究分析了20例头颈部鳞状细胞癌(HNSCC)患者放化疗期间的78份血样,发现升高的cfDNA水平与淋巴结转移治疗前体积、胃造瘘管置入、抗生素使用及明确感染相关,且cfDNA在鉴别中度炎症(RTOG 2-3级)与明确感染方面优于CRP。
要点
- cfDNA升高与淋巴结转移治疗前体积(p=0.0002)、胃造瘘管置入、抗生素使用及明确感染相关。
- cfDNA可鉴别中度炎症(RTOG 2-3级)与明确感染(8.97 ng/ml vs. 16.81 ng/ml,p=0.014),优于CRP(p=0.119)。
- 用二代测序监测肿瘤结局时,感染或用药等混杂因素可能影响ctDNA占总cfDNA的比例,解读需谨慎。
核心结论
- cfDNA水平在放化疗期间与感染相关,可能作为辅助生物标志物帮助治疗决策。
- 用二代测序监测肿瘤结局时,对血浆循环肿瘤DNA(ctDNA)估算水平的解读应谨慎,因为感染或用药等混杂因素可能影响ctDNA在总cfDNA中的比例。
研究设计与样本
- 前瞻性生物标志物研究,共分析20例头颈部鳞状细胞癌(HNSCC)患者的78份血样。
- 血样于治疗前及治疗期间采集,cfDNA水平用荧光法量化,结果与实验室及临床参数进行比较。
主要发现
- 升高的cfDNA水平与淋巴结转移治疗前体积相关(p=0.0002)。
- 胃造瘘管置入者cfDNA中位数20.23 ng/ml vs. 未置入者9.04 ng/ml(p=0.025)。
- 使用抗生素者cfDNA中位数16.47 ng/ml vs. 未使用者9.04 ng/ml(p=0.006)。
- 有明确感染者cfDNA中位数16.81 ng/ml vs. 无感染者9.04 ng/ml(p=0.010)。
- 中度炎症(放射性毒性RTOG 2-3级)与明确感染之间cfDNA差异显著(8.97 ng/ml vs. 16.81 ng/ml,p=0.014),鉴别能力优于CRP水平(p=0.119)。
关键数值与推荐
- 有明确感染者cfDNA中位数16.81 ng/ml vs. 无感染者9.04 ng/ml(p=0.010)。
- 中度炎症(RTOG 2-3级)者cfDNA中位数8.97 ng/ml vs. 明确感染者16.81 ng/ml(p=0.014)。
- CRP在鉴别中度炎症与明确感染方面p=0.119。
- 胃造瘘管置入者cfDNA中位数20.23 ng/ml vs. 未置入者9.04 ng/ml(p=0.025)。
- 使用抗生素者cfDNA中位数16.47 ng/ml vs. 未使用者9.04 ng/ml(p=0.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Radiochemotherapy is a standard treatment option for patients with head and neck cancer (HNSCC). During radiation, local toxicities are common and need to be differentiated from infections. As levels of circulating cell-free DNA (cfDNA) are known to be elevated during infections, cfDNA might complement clinical parameters. The aim of the study was to investigate the dynamics of cfDNA during radiochemotherapy. MATERIAL AND METHODS: In total, 78 blood samples of 20 patients with HNSCC were analysed in this prospective biomarker study. Blood samples were taken before and during treatment. CfDNA levels were quantified fluorometrically and results were compared to laboratory and clinical parameters. RESULTS: Elevated cfDNA levels were associated with the pre-treatment volumes of lymph node metastases (p = 0.0002), gastrostomy tube placement (20.23 ng/ml vs. 9.04 ng/ml (median), p = 0.025), the application of antibiotics (16.47 ng/ml vs. 9.04 ng/ml, p = 0.006) and manifest infections (16.81 ng/ml vs. 9.04 ng/ml, p = 0.010). Furthermore, a significant difference between moderate inflammation (radiation-induced toxicity RTOG grade 2-3) and manifest infections could be observed (8.97 ng/ml vs. 16.81 ng/ml, p = 0.014), allowing for a more pronounced differentiation than by CRP levels (p = 0.119). There might be an association between the application of G-CSF and elevated cfDNA levels. CONCLUSION: CfDNA levels are correlated with infections during radiochemotherapy and could represent an informative complemental biomarker to drive therapeutic decision-making. Estimated levels of circulating cell-free tumour DNA (ctDNA) in plasma should be interpreted cautiously when monitoring tumour outcome by next-generation-sequencing, as confounders like infections or drug application might influence the fraction of ctDNA in total cfDNA.
引用
- Zwirner K, Hilke FJ, Demidov G, et al. Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy. Radiother Oncol. 2018. PMID: 30097252. doi:10.1016/j.radonc.2018.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。